PDE10 Inhibitor Therapy for Tourette Tics and Neurobehavioral Symptoms

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Tourette Syndrome, including neuroleptic drugs, are ineffective for all patients and associated with significant side effects, and there is a lack of effective medications for associated neurobehavioral disorders.

Innovation Solution

Administration of a therapeutically effective amount of a phosphodiesterase 10 (PDE10) inhibitor, specifically a compound of Formula I, or its pharmaceutically acceptable salt, to treat Tourette Syndrome, including in subjects with severe tic scores and neurobehavioral disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If neuroleptic drugs are used to treat Tourette Syndrome, then tic symptoms are reduced in some patients, but significant side effects occur and tics are not entirely eliminated

Engineering Contradiction:

Improveefficacy of treatmentVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pharmacological parameter by switching from neuroleptic drugs to PDE10 inhibitors, which have a different mechanism of action. This parameter change allows for tic reduction without the significant side effects associated with neuroleptics, resolving the contradiction between efficacy and harmful effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent substitutes the mechanical/pharmacological system by replacing neuroleptic drugs with PDE10 inhibitors. This substitution introduces a new therapeutic mechanism that achieves tic control without the adverse effects of the previous system

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If neuroleptic drugs are used to treat Tourette Syndrome, then some patients experience tic reduction, but the treatment does not work for all patients

Engineering Contradiction:

Improveefficacy of treatmentVSAvoidapplicability to all patients

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies universality by developing a PDE10 inhibitor that aims to provide effective treatment across all TS patients regardless of their response to neuroleptics. The compound is designed to address the underlying pathophysiology of TS through a different mechanism, making it potentially applicable to all patients rather than just a subset

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Adaptability or versatility

If medications used to treat ADHD are administered to patients with TS, then neurobehavioral symptoms are addressed, but treatment is complicated due to contraindications

Engineering Contradiction:

Improveability to treat neurobehavioral disordersVSAvoidcomplexity of treatment regimen

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent applies universality by designing a PDE10 inhibitor that can simultaneously address both tic symptoms and neurobehavioral disorders associated with TS. This multi-functional approach eliminates the need for separate medications for ADHD and tics, thereby reducing treatment complexity while maintaining versatility

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent merges the treatment of tics and neurobehavioral disorders into a single therapeutic agent (PDE10 inhibitor). This combination approach simplifies the treatment regimen by replacing multiple contraindicated medications with one compound that addresses both symptom types

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20260076950A1Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome

Publication Date: 2026.03.19 NOEMA PHARMA AG

AI summary

Provided herein are methods of treating Tourette Syndrome in a subject in need thereof by administering to the subject compositions comprising a PDE10 inhibitor. Also disclosed are crystalline solid forms of the compound of Formula I and uses thereof: